ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer

World News: . []

SINGAPORE Aug 10 2018 GLOBE NEWSWIRE -- ASLAN Pharmaceuticals NASDAQASLN (TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europ e, toda...

More news and information about ASLAN PHARMACEUTICALS LIMITED

Published By:

Globe Newswire: 13:19 GMT Friday 10th August 2018

Published: .

Search for other references to "aslan" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us